Pfizer Inc. today announced positive topline results from the final prespecified overall survival analysis of the TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in ...

NEW YORK -- (BUSINESS WIRE)-- Pfizer Inc. (PFE) (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. Read more here.

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.

Pfizer's bid to expand the use of its prostate cancer drug Talzenna was rejected by FDA advisers due to unconvincing data. The company sought to triple the number of eligible patients, but experts ...

(RTTNews) - Pfizer Inc. (PFE) Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi in patients with metastatic castration-resistant ...

Pfizer is already the world's third-largest oncology company based on 1H 2024. Its advanced prostate cancer drug XTANDI revenues rose 28% YoY. TALZENNA revenue rose 77% YoY. The company reported ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI ®, an androgen receptor ...